Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Selinexor i vedlikeholdsterapi etter systemisk terapi for deltakere med p53 villtype, avansert eller tilbakevendende endometriekarsinom (XPORT-EC-042)

28. oktober 2026 oppdatert av: Karyopharm Therapeutics Inc

En fase 3, randomisert, placebokontrollert, dobbeltblind, multisenterforsøk med Selinexor i vedlikeholdsterapi etter systemisk terapi for pasienter med p53 villtype, avansert eller tilbakevendende endometriekarsinom

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

257

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Southport, Australia, 5000
        • The Royal Adelaide Hospital
    • New South Wales
      • Albury, New South Wales, Australia, 2640
        • Border Medical Oncology & Haematology
      • Campbelltown, New South Wales, Australia, 2560
        • Macarthur Cancer Therapy Centre
      • Camperdown, New South Wales, Australia, 2050
        • Chris O'Brien Lifehouse
      • Gosford, New South Wales, Australia, 2250
        • Central Coast LHD - Gosford & Wyong Hospitals
      • New Lambton Heights, New South Wales, Australia, 2305
        • Newcastle Private Hospital
      • Saint Leonards, New South Wales, Australia
        • Royal North Shore Hospital
      • Wentworthville, New South Wales, Australia, 2145
        • Westmead Hospital
    • Queensland
      • Southport, Queensland, Australia, 4215
        • ICON Cancer Centre Southport
      • Toowoomba, Queensland, Australia, 4350
        • Toowoomba Hospital
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Royal Hobart Hospital
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Box Hill Hospital - Eastern Health (Oncology)
      • Clayton, Victoria, Australia, 3168
        • Monash Health
      • Frankston, Victoria, Australia, 3199
        • Frankston Hospital
      • Malvern, Victoria, Australia, 3144
        • Cabrini Health
      • Brussels, Belgia, 1200
        • Cliniques Universitaires St. Luc
      • Ghent, Belgia, 9000
        • AZ Sint Lucas
      • Leuven, Belgia, 3000
        • UZ Leuven
      • Mons, Belgia, 7000
        • CHU Ambroise Pare
      • Namur, Belgia, 5000
        • CHU UCL Namur, Site Sainte-Elisabeth
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Cross Cancer Institute
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret
      • Toronto, Ontario, Canada, M9L 2H9
        • Sunnybrook Research Institute
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Centre Hospitalier de l'Université de Montréal
      • Montreal, Quebec, Canada
        • Hospital Maisonneuve-Rosemont
      • Montreal, Quebec, Canada, H4A3J1
        • McGill University Health Centre (MUHC)
    • Alabama
      • Birmingham, Alabama, Forente stater, 35205
        • The University of Alabama at Birmingham
    • Arizona
      • Phoenix, Arizona, Forente stater, 85016
        • Honor Health
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Davis, California, Forente stater, 95616
        • UC DAVIS
      • Duarte, California, Forente stater, 91010
        • City of Hope National Medical Center
      • Irvine, California, Forente stater, 92618
        • City of Hope at Irvine Lennar
      • Los Alamitos, California, Forente stater, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Forente stater, 90806
        • Long Beach Memorial Medical Center
      • Los Angeles, California, Forente stater, 90095
        • UCLA - Women's Health Clinical Research Unit
      • Palo Alto, California, Forente stater, 94304
        • Stanford University
      • San Francisco, California, Forente stater, 94109
        • California Pacific Medical Center
    • Florida
      • Fort Lauderdale, Florida, Forente stater, 33316
        • Broward Health Medical Center
      • Miami Beach, Florida, Forente stater, 33140
        • Mount Sinai Comprehensive Cancer Center
      • Orlando, Florida, Forente stater, 32804
        • Advent Health
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Emory University
      • Atlanta, Georgia, Forente stater, 30303
        • Grady Hospital
      • Augusta, Georgia, Forente stater, 30912
        • Georgia Cancer Center at Augusta University
    • Illinois
      • Arlington Heights, Illinois, Forente stater, 60005
        • Illinois Cancer Specialists
      • Evanston, Illinois, Forente stater, 60201
        • NorthShore University Health System
    • Indiana
      • Dyer, Indiana, Forente stater, 46311
        • Northwest Cancer Center
      • Goshen, Indiana, Forente stater, 46526
        • Goshen Health
      • Indianapolis, Indiana, Forente stater, 46260
        • St Vincent Hospital
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70119
        • LSU Health Sciences Center New Orleans
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Tufts Medical Center
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Karmanos Cancer Institute
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota
      • Minneapolis, Minnesota, Forente stater, 55404
        • USON - Minnesota Oncology Hematology
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39216
        • St. Dominic's Gynecologic Oncology
    • Missouri
      • Kansas City, Missouri, Forente stater, 64132
        • Midwest Ventures Group HCA MId America Division
    • Montana
      • Billings, Montana, Forente stater, 59101
        • Intermountain Health St. Vincent Regional Hospital
    • Nevada
      • Reno, Nevada, Forente stater, 89511
        • Center Of Hope
    • New York
      • Albany, New York, Forente stater, 12208
        • Women's Cancer Care Associates, LLC
      • Mineola, New York, Forente stater, 11501
        • NYU Langone Hospital-Long Island
      • New Hyde Park, New York, Forente stater, 11042
        • Northwell Health - Zuckerberg Cancer Center
      • New York, New York, Forente stater, 10075
        • Lenox Hill Hospital
      • New York, New York, Forente stater, 10016
        • Perlmutter Cancer Center at NYU Langone Health
      • Rego Park, New York, Forente stater, 11374
        • Northwell Health - Queens Cancer Center
      • Rochester, New York, Forente stater, 14642
        • University of Rochester
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28209
        • Atrium Health Levine Cancer Institute
      • Durham, North Carolina, Forente stater, 27710
        • Duke Cancer Center
    • Ohio
      • Cleveland, Ohio, Forente stater, 44109
        • MetroHealth
      • Columbus, Ohio, Forente stater, 43219
        • Zangmeister Cancer Center
      • Sylvania, Ohio, Forente stater, 43560
        • ProMedica Flower Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, Forente stater, 74146
        • Oklahoma Cancer Specialists and Research Institute, LLC
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Oncology Associates of Oregon
      • Portland, Oregon, Forente stater, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Langhorne, Pennsylvania, Forente stater, 19047
        • Alliance Cancer Specialists
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Magee - Women's Hospital
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Allegheny Health Network - West Penn Hospital
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57105
        • Avera
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37920
        • University of Tennessee Medical Center
      • Memphis, Tennessee, Forente stater, 38103
        • University of Tennessee Health Science Center
    • Texas
      • Austin, Texas, Forente stater, 78731
        • USON - Texas Oncology, Austin Central
      • Dallas, Texas, Forente stater, 75390
        • University of Texas Southwestern Medical Center
      • Dallas, Texas, Forente stater, 75235
        • Parkland Health & Hospital System
      • Dallas, Texas, Forente stater, 75246
        • Texas Oncology - Dallas
      • Houston, Texas, Forente stater, 77030
        • Houston Methodist
      • San Antonio, Texas, Forente stater, 78240
        • Texas Oncology - San Antonio
      • The Woodlands, Texas, Forente stater, 77380
        • Texas Oncology - The Woodlands
      • Tyler, Texas, Forente stater, 75702
        • Texas Oncology, PC, Tyler
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • University of Utah
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • University of Virginia
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • University of Wisconsin Hospital and Clinics
      • Batumi, Georgia, 6000
        • High Technology Hospital Medcenter
      • Tbilisi, Georgia, 0114
        • LTD New Hospitals
      • Tbilisi, Georgia, 0186
        • Caucasus Medical Centre
      • Tbilisi, Georgia, 0112
        • Todua Clinic
      • Tbilisi, Georgia, 0156
        • Tbilisi Cancer Center
      • Tbilisi, Georgia, 0159
        • JSC - K.Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi, Georgia, 0186
        • LTD Innova Medical Center
      • Tbilisi, Georgia, 0186
        • Multiprofile Clinic "Consilium Medulla"
      • Athens, Hellas, 15123
        • Hygeia Hospital
      • Athens, Hellas, 11528
        • Alexandra Hospital
      • Thessaloniki, Hellas, 54645
        • Euromedica General Clinic
      • Cork, Irland, T12 DC4A
        • Cork University Hospital
      • Dublin, Irland, D08 NHY1
        • St. James Hospital
      • Galway, Irland, H91 YR71
        • Galway University
      • Waterford, Irland, X91 ER8E
        • University Hospital Waterford
    • Elm Park
      • Dublin, Elm Park, Irland, D04 T6F4
        • St. Vincent's University Hospital
      • Hadera, Israel, 38100
        • Hillel-Yaffe Medical Center
      • Holon, Israel
        • Wolfson Medical Center
      • Jerusalem, Israel, 91120
        • Hadassah Medical Center
      • Ramat Gan, Israel, 52621
        • Sheba Medical Center
      • Bologna, Italia, 40138
        • IRCCS Azienda Ospedaliero Universitaria di Bologna
      • Brescia, Italia, 25123
        • ASST Spedali Civili Di Brescia
      • Meldola, Italia, 47014
        • IRCCS Istituto Romagnolo Per Lo Studio Del Tumori "Dino Amadori" - IRST S.R.L.
      • Milan, Italia, 20141
        • Instituto Europeo di Oncologia
      • Milan, Italia, 20133
        • Istituto Nazionale dei Tumori IRCCS - MILANO S. C. Ginecologia Oncologica
      • Milan, Italia, 20159
        • Humanitas San Pio X Hospital
      • Milan, Italia, 20132
        • San Raffaele Hospital
      • Monza, Italia, 20900
        • Ospedale San Gerardo - Asst Monza
      • Naples, Italia, 20133
        • "Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - NAPOLI Struttura Complessa Oncologia Medica Uro-Ginecologica"
      • Padova, Italia, 35128
        • Istituto Oncologico Veneto
      • Pisa, Italia, 56127
        • Universita di Pisa
      • Prato, Italia, 59100
        • Nuovo Ospedale di Prato
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli - ROMA
      • Torino, Italia, 10128
        • AO Ordine Mauriziano
      • Torino, Italia, 10124
        • Ospedale Ostetrico Ginecologico Sant'Anna
      • Bratislava, Slovakia, 83310
        • National Cancer Institute
      • Bratislava, Slovakia, 81250
        • St. Elisabeth Cancer Institute
      • Bratislava, Slovakia, 82606
        • UH Bratislava
      • Trenčín, Slovakia, 91101
        • UH Trenčín
      • Badalona, Spania, 08916
        • ICO Badalona
      • Barcelona, Spania, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Spania, 08908
        • Institut Catala d'Oncologia Hospitalet
      • Barcelona, Spania, 08035
        • Hospital Universitari Vall d' Hebrón
      • Córdoba, Spania, 14004
        • Hospital Universitario Reina Sofía
      • Girona, Spania, 17007
        • Institut Catala d'Oncologia de Girona
      • Granada, Spania, 18014
        • Hospital Universitario Virgen de las Nieves
      • Madrid, Spania, 28046
        • Hospital Universitario La Paz
      • Madrid, Spania, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Spania, 28033
        • MD Anderson Cancer Center Madrid
      • Madrid, Spania, 28041
        • H 12 de Octubre
      • Madrid, Spania, 28034
        • Hospital Universitario Ramón y Cajal
      • Murcia, Spania, 30120
        • Virgen de la Arrixaca University Clinical Hospital
      • Málaga, Spania, 29010
        • Hospital Universitatrio Virgen de la Victoria
      • Seville, Spania, 41013
        • Hospital Universitario Virgen del Rocío
      • Valencia, Spania, 46026
        • Hospital LaFe Uacenlia
      • Valencia, Spania, 46009
        • Instituto Valenciano de Oncología
      • Valencia, Spania, 46010
        • Hospital Clínico Universitario de Valencia
      • Zaragoza, Spania, 50009
        • Hospital Miguel Servet
    • Gipuzkoa
      • Donostia / San Sebastian, Gipuzkoa, Spania, 20014
        • Hospital Universitario Donostia
    • Zaragoza
      • Zaragoza, Zaragoza, Spania, 50009
        • Hospital Clínico Universitario Lozano Blesa
      • Seongnam-si, Sør -Korea, 59
        • CHA University/Bundang CHA General Hospital
      • Seoul, Sør -Korea, 03080
        • Seoul National University Hospital
      • Seoul, Sør -Korea, 73
        • Korea University Anam Hospital
      • Kaohsiung City, Taiwan, 833401
        • Kaohsiung Chang Gung Memorial Hospital
      • Taichung, Taiwan, 407219
        • TaiChung Veterans General Hospital
      • Tainan, Taiwan, 71004
        • Chi Mei Medical Center
      • Taipei, Taiwan, 104217
        • Mackay Memorial Hospital
      • Taipei, Taiwan, 23561
        • Taipei Medical University- Shuang Ho Hospital, Ministry of Health and Welfare
      • Taoyuan City, Taiwan, 333
        • Chang Gung Memorial Hospital
      • Brno, Tsjekkia, 60200
        • University Hospital Brno
      • Ostrava, Tsjekkia, 70852
        • University Hospital Ostrava
      • Prague, Tsjekkia, 10034
        • UH Královské Vinohrady
      • Prague, Tsjekkia, 12851
        • General University Hospital in Prague
      • Prague, Tsjekkia, 18100
        • Hospital Na Bulovce
      • Adana, Tyrkia (Türkiye), 34920
        • Adana Baskent Hospital
      • Adana, Tyrkia (Türkiye), 01330
        • Çukurova University
      • Ankara, Tyrkia (Türkiye), 06520
        • Memorial Ankara Hospital
      • Ankara, Tyrkia (Türkiye), 06230
        • Hacettepe University Oncology Hospital
      • Istanbul, Tyrkia (Türkiye), 34303
        • Acibadem Atakent Hospital
      • Istanbul, Tyrkia (Türkiye), 34098
        • Cerrahpasa University
    • Ankara
      • Çankaya, Ankara, Tyrkia (Türkiye), 34093
        • Ankara Baskent Hospital
      • Berlin, Tyskland, 13353
        • Charite Berlin Universitatsmedizin
      • Hamburg, Tyskland, 20246
        • Universitätsklinikum Hamburg Eppendorf
      • Kiel, Tyskland, 24105
        • Universitatsklinikum Schleswig-Holstein
      • Kiel, Tyskland, 01307
        • University Hospital Dresden
      • Krefeld, Tyskland, 47805
        • Helios Klinikum Krefeld
      • Leipzig, Tyskland, 04103
        • Universitätsklinik Leipzig
      • Mainz, Tyskland, 55131
        • Universitätsfrauenklinik Mainz
      • Mannheim, Tyskland, 68167
        • Universitätsmedizin Mannheim
      • Munich, Tyskland, 80337
        • Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe GroBhadern
      • Rostock, Tyskland, 18059
        • Klinikum Südstadt Rostock
      • Ulm, Tyskland, 89075
        • Universitätsfrauenklinik Ulm
      • Debrecen, Ungarn, 4032
        • Unit of Gynecol.Oncol., Dept.Obstet.Gynecol., Clinical Center, University of Debrecen
      • Győr, Ungarn, 9024
        • Petz Aladár University Teaching Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria: Patients must meet all of the following inclusion criteria in order to be eligible to participate in this study:

  • Adults (Aged ≥ 18 years)
  • Histologically confirmed endometrial cancer (endometrioid, serous, undifferentiated, or carcinosarcoma sub-types) that is TP53 wild type by central NGS
  • Must have completed at least 12 weeks of platinum-based chemotherapy (with or without immune checkpoint inhibitors), with a confirmed partial or complete response according to RECIST v1.1
  • Must be able to initiate C1D1 within 3-8 weeks after last platinum dose
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate bone marrow function and organ function

Exclusion Criteria: Patients meeting any of the following exclusion criteria are not eligible to participate in this study:

  • Uterine sarcomas, clear cell or small cell carcinoma with neuroendocrine differentiation
  • Palliative radiotherapy administered within 14 days of intended C1D1
  • Any gastrointestinal dysfunction that could interfere with the absorption of oral study therapy
  • Serious psychiatric or medical conditions that could interfere with study participation or would make study involvement unreasonably hazardous
  • Previous treatment with an XPO1 inhibitor
  • Stable disease or disease progression after platinum-based chemotherapy
  • Pregnancy, breastfeeding, or other legal/ethical restrictions to trial participation
  • Known dMMR/MSI-H EC tumors that are medically eligible to receive an immune checkpoint inhibitor

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Selinexor

Participants will receive a fixed dose of selinexor 60 milligrams (mg) oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.

Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

Andre navn:
  • KPT-330
Placebo komparator: Placebo

Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.

Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Etterforskeren vurderte progresjonsfri overlevelse (PFS) per RECIST V1.1
Tidsramme: Fra randomisering til sykdomsprogresjon (PD) eller død, avhengig av hva som skjer først (opptil 34 måneder)
Fra randomisering til sykdomsprogresjon (PD) eller død, avhengig av hva som skjer først (opptil 34 måneder)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progresjonsfri overlevelse (PFS) som vurdert av en blindet Independent Central Review (BICR), per RECIST V1.1
Tidsramme: Fra randomisering til sykdomsprogresjon (PD) eller død, avhengig av hva som skjer først (opptil 34 måneder)
Fra randomisering til sykdomsprogresjon (PD) eller død, avhengig av hva som skjer først (opptil 34 måneder)
Overall Survival (OS)
Tidsramme: Up to 34 months

Time from randomization to death due to any cause

Up to 34 months
Safety and tolerability of study drug (selinexor and placebo)
Tidsramme: From start of study drug administration up to 34 months

The safety and tolerability of study drug (selinexor and placebo) will be evaluated based on adverse event (AE) reports, physical examination results (including vital signs), and clinical laboratory results, by means of the occurrence, nature, and severity of AEs via Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0.

From start of study drug administration up to 34 months
Time to First Subsequent Therapy (TFST)
Tidsramme: From randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first

From randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)
Time to Second Subsequent Therapy (TSST)
Tidsramme: From randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first

From randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)
Progression-free survival after initiating a next-line treatment (PFS2)
Tidsramme: From randomization until the next-line progression event or death due to any cause, up to 34 months

Time from randomization until the progression event after initiating a next-line treatment or death due to any cause, whichever occurs first

From randomization until the next-line progression event or death due to any cause, up to 34 months
EuroQol-5 Dimensions-5 Levels Quality of Life Questionnaire (EQ-5D-5L)
Tidsramme: From baseline and at specified timepoints up to 34 months

EQ-5D-5L is a generic questionnaire that assesses health status as perceived by the patient across 5 categories (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and overall.

From baseline and at specified timepoints up to 34 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. april 2023

Primær fullføring (Faktiske)

22. mai 2026

Studiet fullført (Antatt)

1. januar 2028

Datoer for studieregistrering

Først innsendt

3. november 2022

Først innsendt som oppfylte QC-kriteriene

3. november 2022

Først lagt ut (Faktiske)

10. november 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere